Skylands Capital’s AbbVie ABBV Stock Holding History

Skylands Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500	Closed	-$67K	–	146
2022 Q3	$67K	Hold	500	–	–	0.01%	133
2022 Q2	$77K	Hold	500	–	–	0.01%	138
2022 Q1	$81K	Hold	500	–	–	0.01%	135
2021 Q4	$68K	Sell	500 -13,850	-97%	-$1.64M	0.01%	132
2021 Q3	$1.55M	Buy	14,350 +9,450	+193%	+$1.08M	0.19%	84
2021 Q2	$552K	Sell	4,900 -1,700	-26%	-$191K	0.07%	109
2021 Q1	$714K	Buy	6,600 +800	+14%	+$85.6K	0.09%	101
2020 Q4	$621K	Buy	+5,800	New	+$557K	0.09%	93

Other funds holding ABBV

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Skylands Capital's ABBV Position: Q4 2022 in Review

Skylands Capital sold out of AbbVie (ABBV) in Q4 2022, closing a stake of 500 shares — an estimated $67K sold.

Skylands Capital first reported a position in ABBV in Q4 2020 and held it in 8 quarters. The position peaked at $1.55M in Q3 2021. 3,168 funds tracked by Wall St. Rank hold ABBV as of Q4 2022.

Skylands Capital reported no remaining AbbVie position as of Q4 2022 after selling out during the quarter.
Skylands Capital sold 500 AbbVie shares in Q4 2022, an estimated $67K.
Skylands Capital first reported a position in AbbVie in Q4 2020 and held it in 8 quarters.
Skylands Capital's AbbVie position peaked at $1.55M in Q3 2021.
3,168 funds tracked by Wall St. Rank held AbbVie as of Q4 2022.

Based on Skylands Capital's 13F filing for Q4 2022, filed 9 Feb 2023.